Sionna Therapeutics (SION) risk factors, FY2024 10-K

Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital

1. 01We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue
2. 02Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates

Risks Related to the Discovery and Development of Our Product Candidates

1. 03complementary modulator candidate from our two most advanced modulator candidates, galicaftor (SION-2222), which has been evaluated in Phase 2 clinical trials conducted by AbbVie, and SION-109, which has been evaluated in a Phase 1 clinical trial
2. 04We are early in our development efforts. If we are unable to successfully develop, receive regulatory approval for and commercialize any product candidate or successfully develop any other product candidate or experience significant delays in doing so, our business will be substantially harmed
3. 05expertise, building a commercial organization or successfully outsourcing commercialization, substantial investment and significant marketing efforts before we generate any revenue from product sales
4. 06combination with other therapies is difficult to predict and dependent on a number of factors that are outside our reasonable control
5. 07The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain the required regulatory approval for any product candidate, our business will be substantially harmed
6. 08Preclinical and clinical product development involves a lengthy and expensive process, with an uncertain outcome
7. 09We may incur additional costs and experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates
8. 10trials, particularly because our NBD1 stabilizer product candidates target the NBD1 domain of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein, a novel target which has not yet been tested in CF patients
9. 11Targeting the NBD1 domain of the CFTR protein is novel, and we do not know whether we will be able to successfully develop any products
10. 12to the standard of care. Given the novelty of our product candidates and the inherent risk in developing a combination or add-on therapy, we may not be able to successfully develop any products
11. 13We may not be able to obtain orphan drug designation or exclusivity for our product candidates, and even if we do, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity
12. 14We may not be able to submit INDs or IND amendments to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed
13. 15If we experience delays or difficulties in the enrollment and/or retention of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected, and our receipt of necessary regulatory approvals could be delayed or prevented
14. 16The results of clinical trials conducted at clinical trial sites outside the U.S. might not be accepted by the FDA, and data developed outside of a foreign jurisdiction similarly might not be accepted by such foreign regulatory authority
15. 17If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates or increase the product yield of its manufacturing, then our manufacturing costs may increase and commercialization may be delayed
16. 18Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
17. 19Certain of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue
18. 20We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success

Risks Related to Our Dependence on Third Parties

1. 21If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates
2. 22We currently rely on, and in the future intend to rely on, third parties to conduct a significant portion of our clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials

Risks Related to Our Intellectual Property

1. 23If we fail to comply with our obligations in any current intellectual property licenses with third parties, or fail to obtain such licenses in the future, we could lose rights that are material to our business
2. 24Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any future patents we obtain
3. 25We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful
4. 26Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain
5. 27found to have willfully infringed the patent at issue. A finding of infringement that prevents us from commercializing our product candidates, requires us to redesign our products, or forces us to cease some of our business operations could materially harm our business
6. 28We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or trade secrets of third parties
7. 29We may be subject to claims challenging the inventorship or ownership of our intellectual property, including any patents we obtain
8. 30Reliance on third parties requires us to share trade secrets, which increases the possibility that trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information
9. 31We may enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
10. 32Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
11. 33Intellectual property rights do not necessarily address all potential threats to our competitive advantage
12. 34If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed

Risks Related to Legal and Regulatory Compliance Matters

1. 35Even if we obtain regulatory approvals for our product candidates or any future product candidates, they will remain subject to ongoing regulatory oversight
2. 36Healthcare and other reform initiatives may have an adverse impact on our business and results of operations

Risks Related to the Commercialization of Our Product Candidates

1. 37Even if any of our product candidates receive marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
2. 38and adequate reimbursement. Even if we are able to demonstrate our product candidates’ safety and efficacy to the FDA and other regulators and receive approval, concerns in the medical community related to the comparative efficacy or side effect profile of our products may hinder market acceptance and uptake
3. 39Any failure by one or more of our product candidates that obtains regulatory approvals to achieve market acceptance or commercial success would adversely affect our business prospects
4. 40The success of our product candidates or any future product candidate will depend significantly on coverage and adequate reimbursement by third party payors or the willingness of patients to pay for these products if not covered
5. 41The market for our product candidates may be smaller than we estimate
6. 42Clinical trial and product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and limit commercialization of any products that we may develop

Risks Related to Our Business Operations, Employee Matters and Managing Our Growth

1. 43Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel
2. 44We expect to expand our clinical development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
3. 45Our business could be affected by litigation, government investigations and enforcement actions
4. 46Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements
5. 47If our third-party manufacturers or suppliers do not comply with laws regulating the protection of the environment and health and human safety, our business could be affected adversely
6. 48Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities
7. 49Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses

Risks Related to Ownership of Our Common Stock

1. 50Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations
2. 51The trading price of the shares of our common stock may be volatile, and investors could lose all or part of their investment
3. 52We may not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq
4. 53Sales of a substantial number of shares of our common stock by our stockholders in the public market could cause the market price of our common stock to drop significantly, even if our business is doing well
5. 54Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result
6. 55Our executive officers, directors, principal stockholders, and their respective affiliates own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
7. 56We do not anticipate paying any cash dividends on our common stock in the foreseeable future
8. 57Our bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees
9. 58experienced by us or the third parties upon whom we rely. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences
10. 59transparency, deceptive, unfair or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, including the Federal Trade Commission, or other adverse consequences
11. 60If we fail to maintain an effective system of internal controls over financial reporting, our ability to produce accurate financial statements on a timely basis could be impaired
12. 61Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
13. 62We might not be able to utilize a significant portion of our net operating loss carryforwards
14. 63New tax laws or regulations, changes to existing tax laws or regulations or changes in their application to us may have a material adverse effect on our business, cash flows, financial condition or results of operations
15. 64We are eligible to be treated as an “emerging growth company” and a “smaller reporting company” and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors
16. 65We will incur increased costs and demands upon management as a result of being a public company
17. 66Unstable global economic and geopolitical conditions could adversely affect our business, financial condition, stock price, and results of operations
18. 67We may become involved in litigation that could divert management’s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages